XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Notes Tables |
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] |
|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Cash and cash equivalents |  | $ | 3,868 |  |  | $ | 7,504 |
Restricted cash included in other assets |  |  | 152 |  |  |  | 475 |
Total cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets |  | $ | 4,020 |  |  | $ | 7,979 |
Schedules of Concentration of Risk, by Product [Table Text Block] |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Avenova Spray |  | $ | 1,939 |  |  | $ | 2,145 |  |  | $ | 5,778 |  |  | $ | 6,358 |
DERMAdoctor |  |  | 1,319 |  |  |  | — |  |  |  | 3,115 |  |  |  | — |
NeutroPhase |  |  | — |  |  |  | — |  |  |  | 657 |  |  |  | 175 |
Other products |  |  | 558 |  |  |  | 114 |  |  |  | 1,193 |  |  |  | 479 |
Total product revenue, net |  |  | 3,816 |  |  |  | 2,259 |  |  |  | 10,743 |  |  |  | 7,012 |
Other revenue, net |  |  | 10 |  |  |  | 6 |  |  |  | 18 |  |  |  | 19 |
Total sales, net |  | $ | 3,826 |  |  | $ | 2,265 |  |  | $ | 10,761 |  |  | $ | 7,031 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] |
|  | September 30, |  |  | December 31, |
Major distribution partner |  | 2022 |  |  | 2021 |
Avenova Spray Pharmacy Distributor A |  |  | 24 | % |  |  | 11 | %
Avenova Spray Pharmacy Distributor B |  |  | * | % |  |  | 13 | %
Major U.S. Retailer A |  |  | 20 | % |  |  | 33 | %
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] |
|  | Three Months Ended September 30, 2022 |  |  | Nine Months Ended September 30, 2022 |
|  | As Previously Reported |  |  | Selling Commissions |  |  | Fulfillment Fees |  |  | As Revised |  |  | As Previously Reported |  |  | Selling Commissions |  |  | Fulfillment Fees |  |  | As Revised |
Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 3,268 |  |  | $ | 265 |  |  | $ | 283 |  |  | $ | 3,816 |  |  | $ | 8,934 |  |  | $ | 851 |  |  | $ | 959 |  |  | $ | 10,743 |
Product cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product cost of goods sold |  |  | 1,168 |  |  |  | - |  |  |  | 283 |  |  |  | 1,451 |  |  |  | 3,776 |  |  |  | - |  |  |  | 959 |  |  |  | 4,735 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 1,570 |  |  |  | 265 |  |  |  | - |  |  |  | 1,835 |  |  |  | 5,009 |  |  |  | 851 |  |  |  | - |  |  |  | 5,860 |
Net loss and comprehensive loss |  |  | (136 | ) |  |  | - |  |  |  | - |  |  |  | (136 | ) |  |  | (2,402 | ) |  |  | - |  |  |  | - |  |  |  | (2,402 | )
Net loss per share (basic and diluted) |  |  | (0.10 | ) |  |  | - |  |  |  | - |  |  |  | (0.10 | ) |  |  | (0.15 | ) |  |  | - |  |  |  | - |  |  |  | (0.15 | )
|  | Three Months Ended September 30, 2021 |  |  | Nine Months Ended September 30, 2021 |
|  | As Previously Reported |  |  | Selling Commissions |  |  | Fulfillment Fees |  |  | As Revised |  |  | As Previously Reported |  |  | Selling Commissions |  |  | Fulfillment Fees |  |  | As Revised |
Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 1,834 |  |  | $ | 206 |  |  | $ | 219 |  |  | $ | 2,259 |  |  | $ | 5,761 |  |  | $ | 619 |  |  | $ | 632 |  |  | $ | 7,012 |
Product cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product cost of goods sold |  |  | 493 |  |  |  |  |  |  |  | 219 |  |  |  | 712 |  |  |  | 1,562 |  |  |  |  |  |  |  | 632 |  |  |  | 2,194 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 1,855 |  |  |  | 206 |  |  |  |  |  |  |  | 2,061 |  |  |  | 5,323 |  |  |  | 619 |  |  |  |  |  |  |  | 5,942 |
Net loss and comprehensive loss |  |  | (2,289 | ) |  |  | - |  |  |  | - |  |  |  | (2,289 | ) |  |  | (5,666 | ) |  |  | - |  |  |  | - |  |  |  | (5,666 | )
Net loss per share (basic and diluted) |  |  | (0.05 | ) |  |  | - |  |  |  | - |  |  |  | (0.05 | ) |  |  | (0.13 | ) |  |  | - |  |  |  | - |  |  |  | (0.13 | )
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
Numerator |  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net loss |  | $ | (136 | ) |  | $ | (2,289 | ) |  | $ | (2,402 | ) |  | $ | (5,666 | )
Less: Increase in accumulated deficit due to Series B Preferred Stock conversion price |  |  | 5,657 |  |  |  | — |  |  |  | 5,657 |  |  |  | — |
Net loss attributable to common stockholders, basic and diluted |  | $ | (5,793 | ) |  | $ | (2,289 | ) |  | $ | (8,059 | ) |  | $ | (5,666 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding, basic and diluted |  |  | 56,133 |  |  |  | 44,921 |  |  |  | 53,007 |  |  |  | 43,100 |
Net loss per share, basic and diluted |  | $ | (0.10 | ) |  | $ | (0.05 | ) |  | $ | (0.15 | ) |  | $ | (0.13 | )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
|  | As of September 30, |
|  | 2022 |  |  | 2021 |
Series B Preferred Stock common stock equivalents |  |  | 64,561 |  |  |  | — |
Stock options |  |  | 4,743 |  |  |  | 3,947 |
Stock warrants |  |  | 2,282 |  |  |  | 7,082 |
|  |  | 71,586 |  |  |  | 11,029 |

X
- Definition Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents. + References No definition available. + Details
Name: | nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the concentration of risk by product type. + References No definition available. + Details
Name: | nby_SchedulesOfConcentrationOfRiskByProductTableTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration